α1-抗胰蛋白酶基因治疗糖尿病疗效观察

The clinical effect of α1-antitrypsin gene therapy in treating diabetes

目的 观察α1-抗胰蛋白酶基因治疗糖尿病的临床效果。方法 81例1型糖尿病患者按数字表法随机分为常规治疗组、胰岛干细胞移植组和基因治疗组,各27例,常规治疗组进行胰岛素注射降糖保守治疗,胰岛干细胞移植组进行胰岛细胞移植,基因治疗组接受α1-抗胰蛋白酶基因的干细胞治疗,观察比较三组的临床治疗效果。结果 基因治疗组术后5个测定时间点血清胰岛素浓度均明显高于胰岛干细胞移植组和常规治疗组（F=1 349.379、1 831.186、1 068.173、416.080、257.810,均P＜0.05）;基因治疗组口服葡萄糖后6个测定时间点血糖浓度均明显低于胰岛干细胞治疗组和常规治疗组（F=1 212.243、586.057、962.495、582.887、650.015、1 181.808,均P＜0.05）;基因治疗组术后移植部位炎性细胞浸润程度明显轻于胰岛干细胞治疗组。结论 α1-抗胰蛋白酶基因治疗可以显著提高糖尿病的治疗效果,值得临床推广应用。

Objective To observe the clinical effect of α1-antitrypsin gene therapy in the treatment of diabetes.Methods 81 cases with type 1 diabetes were randomly divided into conventional treatment group,islet stem cell transplantation group and gene therapy group,27 cases in each group.The conventional treatment group received the insulin therapy,the stem cell transplantation group received the islet cell transplantation,and the gene therapy group received stem cell therapy of α1-antitrypsin gene.The clinical effect of these three groups were observed.Results The insulin concentration of the gene therapy group was significantly higher than the islet stem cell transplantation group and the conventional treatment group at five time points（F=1 349.379,1 831.186,1 068.173,416.080,257.810,all P〈0.05）.The glucose concentration of the gene therapy group was significantly lower than the other two groups at six time points（F=1 212.243,586.057,962.495,582.887,650.015,1 181.808,all P〈0.05）.The degree of inflammatory cell infiltration in the gene therapy group was significantly lighter than in the islet stem cell transplantation group.Conclusion α1-antitrypsin gene therapy can significantly improve the therapeutic effect of diabetes,which is worthy of clinical application.